Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > HAS GLP TOXICOLOGY ANALYSIS OF RUTHERRIN NOT BEEN DONE

<< Previous

Bullboard Posts

Next >>

Post by Tarbabyon Aug 23, 2024 2:44pm

187 Views

Post# 36193832

HAS GLP TOXICOLOGY ANALYSIS OF RUTHERRIN NOT BEEN DONE

ROGER has several times stated this is PENDING...Shouldnt toxicology analysis be JOB1 with any newly developed drug.. Dont they need Health Canada approval of Rutherrin before they can do any clinical trials which involve iv injection into humans.? Like xray activation trials or Metformin enhancement trials as he recently described in news releases.

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project